

- (v) का.आ. 4100(अ), दिनांक 21 दिसम्बर, 2016;  
 (vi) का.आ. 39(अ), दिनांक 3 जनवरी, 2019;  
 (vii) का.आ. 508(अ), दिनांक 1 फरवरी, 2021;  
 (viii) का.आ. 2899(अ), दिनांक 20 जुलाई, 2021; तथा  
 (ix) का.आ. 3249(अ), दिनांक 12 अगस्त, 2021

**MINISTRY OF CHEMICALS AND FERTILIZERS**

**(Department of Pharmaceuticals)**

**NOTIFICATION**

New Delhi, the 11th November, 2022

**S.O. 5249 (E).**—In exercise of the powers conferred by section 3 of the Essential Commodities Act, 1955 (10 of 1955), the Central Government hereby makes the following order further to amend the Drugs (Prices Control) Order, 2013, namely:—

- Short title and commencement.** - (1) This Order may be called the Drugs (Prices Control) Amendment Order, 2022.  
 (2) It shall come into force on the date of its publication in the Official Gazette.
- In the Drugs (Prices Control) Order, 2013, for Schedule-I, the following Schedule shall be substituted, namely: -

**“SCHEDULE-I**

**National List of Essential Medicines (NLEM) 2022**

**[See paragraphs-2(t) and 2(zb)]**

(Symbols P,S and T appearing in this Schedule denote essentiality at Primary, Secondary and Tertiary levels respectively)

<b>Section 1</b>			
<b>Medicines used in Anaesthesia</b>			
<b>1.1- General Anaesthetics and Oxygen</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
1.1.1	Halothane	S,T	Liquid for inhalation
1.1.2	Isoflurane	S,T	Liquid for inhalation
1.1.3	Ketamine	P,S,T	Injection 10 mg/mL Injection 50 mg/mL
1.1.4	Nitrous oxide	P,S,T	As licensed for medical purpose
1.1.5	Oxygen*	P,S,T	As licensed for medical purpose
1.1.6	Propofol	P,S,T	Injection 10 mg/mL
1.1.7	Sevoflurane	S,T	Liquid for inhalation
1.1.8	Thiopentone	P,S,T	Powder for injection 0.5 g Powder for injection 1 g

<i>*Oxygen is also listed in Section 27.5 - Medicines for COVID-19 management</i>			
<b>1.2-Local Anaesthetics</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
1.2.1	Bupivacaine	S,T	Injection 0.25 % Injection 0.5 % Injection 0.5 % with 7.5 % glucose
1.2.2	Lignocaine*	P,S,T	Topical forms 2-5 % Injection 1 % Injection 2 % Injection 5 % with 7.5 % glucose
1.2.3	Lignocaine (A) + Adrenaline (B)	P,S,T	Injection 1% (A) + 1:200000 (5 mcg/mL) (B) Injection 2% (A) + 1:200000 (5 mcg/mL) (B)
<b>1.3- Preoperative Medication and Sedation for Short Term Procedures</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
1.3.1	Atropine**	P,S,T	Injection 0.6 mg/mL
<i>*Lignocaine formulations are also listed in Section 10.2.5 cardiovascular medicines- Antiarrhythmic medicines</i>			
<i>**Atropine formulations are also listed in –</i>			
<i>A. Section 4.2.1 - Antidotes and Other Substances used in Management of Poisonings/Envenomation - Specific</i>			
<i>B. Section 21.5.1 - Ophthalmological Medicines- Mydriatics</i>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
1.3.2	Glycopyrrolate	S,T	Injection 0.2 mg/mL
1.3.3	Midazolam*	P,S,T	Tablet 7.5 mg Nasal Spray 0.5mg Nasal Spray 1.25 mg Injection 1 mg/mL Injection 5 mg/mL
1.3.4	Morphine**	P,S,T	Injection 10 mg/mL Injection 15 mg/mL
<b>Section 1.4 -Muscle Relaxants and Cholinesterase Inhibitors</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
1.4.1	Atracurium	S,T	Injection 10 mg/mL

1.4.2	Baclofen	S,T	Tablet 5 mg Tablet 10 mg Tablet 20 mg
-------	----------	-----	---

\*Midazolam formulations are also listed in -

A. **Section 5.1.7-** Medicines used in Neurological Disorders Anticonvulsants/ Antiepileptics

B. **Section 7.4.12-** Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care

\*\*Morphine formulations are also listed in -

A. **Section 2.2.2-** Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Opioid Analgesics

B. **Section 7.4.13 -** Anti-cancer agents including immunosuppressives, and medicines used in Palliative Care

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
1.4.3	Neostigmine*	S,T	Tablet 15 mg Injection 0.5 mg/mL
1.4.4	Succinylcholine	S,T	Injection 50 mg/mL
1.4.5	Vecuronium	S,T	Powder for injection 4 mg Powder for injection 10 mg

## Section 2

### Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders

#### 2.1 - Non-opioid Analgesics, Antipyretics and Non-steroidal Anti-inflammatory Drugs

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
2.1.1	Acetylsalicylic acid**	P,S,T	Tablet 300 mg to 500 mg Effervescent/ Dispersible/ Enteric coated Tablet 300 mg to 500 mg

\*Neostigmine formulations are also listed in **Section 4.2.8 - Antidotes and Other substances used in Management of poisoning/Envenomation - Specific**

\*\*Acetylsalicylic acid formulations are also listed in -

A. **Section 5.2.1 -** Medicines used in Neurological Disorders Antimigraine medicines

B. **Section 10.5.1 -** Cardiovascular medicines -Antithrombotic Medicines (Cardiovascular/ Cerebrovascular) - Antiplatelet and Antithrombotic Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
2.1.2	Diclofenac	P,S,T	Tablet 50 mg Injection 25 mg/mL
2.1.3	Ibuprofen*	P,S,T	Tablet 200 mg Tablet 400 mg

			Oral liquid 100 mg/5 mL (p)
2.1.4	Mefenamic acid	P,S,T	Tablet 250 mg Oral liquid 100 mg/5 mL (p)
2.1.5	Paracetamol**	P,S,T	Tablet 500 mg Tablet 650 mg Oral liquid 120 mg/5 mL (p) Oral Liquid 125 mg/5 mL (p) Oral Liquid 250 mg/5 mL (p) Injection 150 mg/ mL Suppository 80 mg Suppository 170 mg
<b>2.2-Opioid Analgesics</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
2.2.1	Fentanyl	S,T	Injection 50 mcg/mL
*Ibuprofen formulations are also listed in <b>Section 5.2.2 - Medicines used in Neurological Disorders-Antimigraine Medicines</b>			
** Paracetamol formulations are also listed in -			
<b>A. Section 5.2.3 - Medicines used in Neurological Disorders-Antimigraine Medicines</b>			
<b>B. Section 27.4 - Medicines for COVID- 19 Management</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
2.2.2	Morphine*	P,S,T	Tablet 10 mg Injection 10 mg/mL Injection 15 mg/mL
2.2.3	Tramadol**	S,T	Capsule 50 mg Capsule 100 mg Injection 50 mg/mL
<b>2.3-Medicines used to treat Gout</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
2.3.1	Allopurinol***	P,S,T	Tablet 100 mg Tablet 300 mg
2.3.2	Colchicine	P,S,T	Tablet 0.5 mg
*Morphine formulations are also listed in –			
<b>A. Section 1.3.4 - Medicines used in Anaesthesia - Preoperative medication and sedation for short term procedures</b>			
<b>B. Section 7.4.13 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care</b>			

**\*\* Tramadol formulations are also listed in-**

**Section 7.4.15 - Tramadol formulations are also listed in Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

**\*\*\* Allopurinol formulations are also listed in-**

**Section 7.4.1 - Allopurinol formulations are also listed in Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

#### **2.4-Disease Modifying Agents used in Rheumatoid Disorders**

	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
2.4.1	Azathioprine*	S,T	Tablet 25 mg (p) Tablet 50 mg
2.4.2	Hydroxychloroquine	P,S,T	Tablet 200 mg Tablet 400 mg
2.4.3	Methotrexate**	P,S,T	Tablet 2.5 mg Tablet 5 mg Tablet 10 mg
2.4.4	Sulfasalazine	S,T	Tablet 500 mg

#### **Section 3**

#### **Antiallergics and Medicines used in Anaphylaxis**

	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
3.1	Adrenaline	P,S,T	Injection 1 mg/mL
3.2	Cetirizine	P,S,T	Tablet 10 mg Oral liquid 5 mg/5 mL (p)

**\* Azathioprine formulations are also listed in Section 7.3.1 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

**\*\* Methotrexate formulations are also listed in Section 7.1.30 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
3.3	Dexamethasone*	P,S,T	Tablet 0.5 mg Tablet 2 mg Tablet 4 mg  Oral liquid 0.5 mg/5 mL (p) Injection 4 mg/mL
3.4	Hydrocortisone**	P,S,T	Tablet 5 mg Tablet 10 mg Powder for Injection 100 mg Powder for Injection 200 mg

3.5	Pheniramine	P,S,T	Injection 22.75 mg/mL
3.6	Prednisolone***	P,S,T	Tablet 5 mg Tablet 10 mg Tablet 20 mg Oral liquid 5 mg/5 mL (p) Oral liquid 15 mg/5 mL (p)

\*Dexamethasone formulations are also listed in -

**A. Section 7.4.3 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

**B. Section 18.1.1 - Hormones, other Endocrine Medicines and Contraceptives - Adrenal Hormones and Synthetic Substitutes**

**C. Section 27.1 - Medicines for COVID- 19 Management**

\*\* Hydrocortisone formulations are also listed in **Section 18.1.3 - Hormones, other Endocrine Medicines and Contraceptives- Adrenal Hormones and Synthetic Substitutes**

\*\*\*Prednisolone formulations are also listed in -

**A. Section 7.2.4 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Hormones and Anti-Hormones used in cancer therapy**

**B. Section 18.1.5 - Hormones, other Endocrine Medicines and Contraceptives –Adrenal Hormones and Synthetic Substitutes**

**C. Section 21.2.1 - Ophthalmological Medicines- Anti-inflammatory Medicine**

#### Section 4

#### Antidotes and Other Substances used in Management of Poisonings/Envenomation

##### 4.1-Nonspecific

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
4.1.1	Activated Charcoal	P,S,T	Powder (as licensed)

##### 4.2 Specific

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
4.2.1	Atropine*	P,S,T	Injection 0.6 mg/mL
4.2.2	Calcium gluconate**	P,S,T	Injection 100 mg/mL
4.2.3	D- Penicillamine	P,S,T	Capsule 150 mg (p) Capsule 250 mg
4.2.4	Desferrioxamine	S,T	Powder for injection 500 mg
4.2.5	Methylthionium chloride (Methylene blue)	S,T	Injection 10 mg/mL

\*Atropine formulations are also listed in -

**A. Section 1.3.1 - Medicines used in Anaesthesia -Preoperative Medication and Sedation for short term procedures**

**B. Section 21.5.1 - Ophthalmological Medicines- Mydriatics**

**\*\* Calcium gluconate formulations are also listed in Section 26.3 - Vitamins and minerals**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
4.2.6	N-acetylcysteine	P,S,T	Sachet 200 mg Injection 200 mg/mL
4.2.7	Naloxone	P,S,T	Injection 0.4 mg/mL
4.2.8	Neostigmine*	P,S,T	Injection 0.5 mg/mL
4.2.9	Pralidoxime chloride (2-PAM)	P,S,T	Injection 25 mg/mL
4.2.10	Snake venom antiserum**	P,S,T	Soluble/ liquid polyvalent -As licensed Lyophilized polyvalent -As licensed
4.2.11	Sodium nitrite	S,T	Injection 30 mg/mL
4.2.12	Sodium thiosulphate	S,T	Injection 250 mg/mL

\* Neostigmine formulations are also listed in Section 1.4.3 - Medicines used in Anaesthesia - Muscle relaxants and cholinesterase inhibitors

\*\* Snake Venom antiserum is also listed in Section 19.2.7. - Immunologicals -Sera and immunoglobulins (Liquid/ Lyophilized)

### Section 5

#### Medicines used in Neurological Disorders

##### Section 5.1-Anticonvulsants/ Antiepileptics

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
5.1.1	Carbamazepine*	P,S,T	Tablet 100 mg Tablet 200 mg Tablet 400 mg Modified Release – Tablet 200 mg Tablet 400 mg Oral liquid 100 mg/5 mL (p)
5.1.2	Clobazam	S,T	Tablet 5 mg Tablet 10 mg
5.1.3	Diazepam**	P,S,T	Oral liquid 2 mg/5 mL (p) Injection 5 mg/mL Suppository 5 mg
5.1.4	Levetiracetam	S,T	Tablet 250 mg Tablet 500 mg Tablet 750 mg Modified Release Tablet 750 mg Oral liquid 100 mg/mL (p)

			Injection 100 mg/mL
5.1.5	Lorazepam	P,S,T	Tablet 1 mg Tablet 2 mg Injection 2 mg/mL Injection 4 mg/mL
*Carbamazepine formulations are also listed in <b>Section 23.2.2.3</b> Medicines used in treatment of Psychiatric disorder - Medicines used in Bipolar disorders			
** Diazepam formulations are also listed in <b>Section 7.4.4</b> - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
5.1.6	Magnesium sulphate	S,T	Injection 500 mg/mL
5.1.7	Midazolam*	P,S,T	Tablet 7.5 mg Tablet 15 mg Nasal Spray 0.5 mg/actuation Nasal Spray 1.25 mg/actuation Injection 1 mg/mL Injection 5 mg/mL
5.1.8	Phenobarbitone	P,S,T	Tablet 30 mg Tablet 60 mg Oral liquid 20 mg/5 mL (p)
		S,T	Injection 200 mg/mL
5.1.9	Phenytoin	P,S,T	Tablet 50 mg Tablet 100 mg Tablet 300 mg Modified Release Tablet 300 mg Oral liquid 30 mg/5 mL (p) Oral liquid 125 mg/5 mL (p) Injection 25 mg/mL Injection 50 mg/mL
*Midazolam formulations are also listed in –			
<b>A. Section 1.3.3</b> - Medicines used in Anaesthesia - Preoperative Medication and Sedation for short term procedures			
<b>B. Section 7.4.12</b> - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
			Tablet 200 mg Tablet 300 mg



5.1.10	Sodium Valproate*	P,S,T	Tablet 500 mg Modified Release – Tablet 300 mg Tablet 500 mg Oral liquid 200 mg/5 mL (p)
		S,T	Injection 100 mg/mL

**Section 5.2- Antimigraine Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
5.2.1	Acetylsalicylicacid**	P,S,T	Tablet 300 mg to 500 mg Effervescent/ Dispersible/ Enteric coated Tablet 300 mg to 500 mg

\*Sodium Valproate formulations are also listed in-

**Section 23.2.2.2 - Medicines used in treatment of Psychiatric Disorders -Medicines used in Bipolar disorders- Medicines used in mood disorders**

\*\*Acetylsalicylic acid formulations are also listed in -

**A. Section 2.1.1 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory**

*Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Non-Opioid Analgesics, Antipyretics and Non-Steroidal Anti-Inflammatory Drugs*

**B. Section 10.5.1 - Cardiovascular medicines- Antiplatelet and Antithrombotic Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
5.2.2	Ibuprofen*	P,S,T	Tablet 200 mg Tablet 400 mg Oral liquid 100 mg/5 mL (p)
5.2.3	Paracetamol**	P,S,T	Tablet 500 mg Tablet 650 mg Oral liquid 120 mg/5mL (p) Oral Liquid 125 mg/5mL (p) Oral Liquid 250 mg/5mL (p)
5.2.4	Sumatriptan	P,S,T	Tablet 25 mg Tablet 50 mg

**Section 5.2.1 - For Prophylaxis**

5.2.1.1	Amitriptyline***	P,S,T	Tablet 10 mg Tablet 25 mg Tablet 75 mg
---------	------------------	-------	--

\*Ibuprofen formulations are also listed in **Section 2.1.3 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders Non-opioid Analgesics, Antipyretics and Non-steroidal Anti-inflammatory Drugs**

**\*\*Paracetamol formulations are also listed in -**

**A. Section 2.1.5 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory**

*Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Non-opioid analgesics, antipyretics and nonsteroidal anti-inflammatory medicines*

**B. Section 27.4 - Medicines for COVID- 19 management**

**\*\*\* Amitriptyline formulations are also listed in -**

**A. Section 7.4.2 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care-**

**B. Section 23.2.1.1 - Medicines used in treatment of Psychiatric Disorders -Medicines used in mood disorders- Medicines used in depressive disorders**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
5.2.1.2	Flunarizine	P,S,T	Tablet 5 mg Tablet 10 mg
5.2.1.3	Propranolol	P,S,T	Tablet 10 mg Tablet 20 mg Tablet 40 mg

### Section 5.3- Antiparkinsonism Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
5.3.1	Levodopa (A) + Carbidopa (B)	P,S,T	Tablet 100 mg (A) + 10 mg (B) Tablet 100 mg (A) + 25 mg (B) Tablet 250 mg (A) + 25 mg (B) Modified Release – Tablet 100 mg (A) + 25 mg (B) Tablet 200 mg (A) + 50 mg (B)
5.3.2	Trihexyphenidyl	P,S,T	Tablet 2 mg

### Section 5.4-Medicines used in Dementia

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
5.4.1	Donepezil	S,T	Tablet 5 mg Tablet 10 mg

## Section 6

### Anti-infective Medicines

#### 6.1-Anthelmintics

##### 6.1.1- Intestinal Anthelmintics

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
			Tablet 400 mg

6.1.1.1	Albendazole*	P,S,T	Chewable Tablet 400 mg Oral liquid 200 mg/5 mL (p)
6.1.1.2	Mebendazole	P,S,T	Tablet 100 mg Oral liquid 100 mg/5 mL (p)
<b>6.1.2 Antifilarial</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.1.2.1	Albendazole*	P,S,T	Tablet 400 mg Chewable Tablet 400 mg Oral liquid 200 mg/5 mL (p)
6.1.2.2	Diethylcarbamazine(DEC)	P,S,T	Tablet 50 mg Tablet 100 mg Oral liquid 120 mg/5 mL (p)
<i>* Albendazole formulations are also listed Section 6.1.1.1 - in Anti-infective Medicines-Antifilarial</i>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.1.2.3	Ivermectin	P,S,T	Tablet 6 mg Tablet 12 mg
<b>6.1.3 - Anti-schistosomal and Anti-trematodal Medicine</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.1.3.1	Praziquantel	S,T	Tablet 600 mg
<b>6.2-Antibacterials</b>			
<b>6.2.1 Beta-lactam Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.2.1.1	Amoxicillin	P,S,T	Capsule 250 mg Capsule 500 mg Oral liquid 125 mg/5 mL (p) Oral liquid 250 mg/5 mL (p) Powder for Injection 250 mg Powder for Injection 500 mg Powder for injection 1000 mg
6.2.1.2	Amoxicillin (A) + Clavulanic acid (B)	P,S,T	Tablet 500 mg (A) + 125 mg (B) Oral liquid 200 mg (A) + 28.5 mg (B)/5 mL (p) Dry Syrup 125 mg (A) + 31.25 (B)/ 5 mL (p)

		S,T	Powder for Injection 500 mg (A) + 100 mg (B) Powder for Injection 1 g (A) +200 mg (B)
6.2.1.3	Ampicillin	P,S,T	Powder for Injection 500 mg Powder for Injection 1000 mg
6.2.1.4	Benzathine benzylpenicillin	P,S,T	Powder for Injection 6 lac units Powder for Injection 12 lac units Powder for injection 24 lac units
6.2.1.5	Benzylnicillin	P,S,T	Powder for injection 5 lac units Powder for injection 10 lac units
6.2.1.6	Cefadroxil	P,S,T	Tablet 500 mg Tablet 100 mg Oral liquid 125 mg/5 mL (p)
6.2.1.7	Cefazolin	P,S,T	Powder for Injection 500 mg Powder for Injection 1000 mg
6.2.1.8	Cefixime	S,T	Tablet 200 mg Tablet 400 mg Oral liquid 50 mg/5 mL (p) Oral liquid 100 mg/5 mL (p)
6.2.1.9	Cefotaxime*	S,T	Powder for Injection 250 mg Powder for Injection 500 mg Powder for Injection 1000 mg
<i>*Cefotaxime formulations are also listed in Section 6.7.5.2 - Anti-infective Medicines- Antiviral Medicines- Medicines for treating Opportunistic Infections in People living with HIV</i>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.2.1.10	Ceftazidime	S,T	Powder for Injection 250 mg Powder for Injection 1000 mg
6.2.1.11	Ceftriaxone	S,T	Powder for Injection 250 mg Powder for Injection 500 mg Powder for Injection 1000 mg Powder for Injection 2000 mg
6.2.1.12	Cloxacillin	P,S,T	Capsule 250 mg Capsule 500 mg Oral Liquid 125 mg/5 mL (p) Powder for Injection 250 mg
	Piperacillin (A) +Tazobactam (B)		Powder for Injection 1000 mg (A) + 125 mg (B) Powder for Injection 2000 mg

6.2.1.13		T	(A) + 250 mg (B) Powder for Injection 4000 mg (A) + 500 mg (B)
6.2.1.14	Meropenem	T	Powder for Injection 500 mg (astrihydrate) Powder for Injection 1000 mg (as trihydrate)

**6.2.2 - Other Antibacterials**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.2.2.1	Azithromycin*	P,S,T	Tablet 250 mg Tablet 500 mg Oral liquid 200 mg/5 mL (p) Powder for Injection 500 mg
6.2.2.2	Cefuroxime	P,S,T	Tablet 500 mg Oral liquid 125 mg/ 5 mL (p) Injection 1500 mg

\*Azithromycin formulations are also listed in **Section 6.7.6.1 Anti-infective Medicines - Medicines used in the management of HIV- Additional Medicines for Syndromic Management of Sexually Transmitted Infections**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.2.2.3	Ciprofloxacin*	P,S,T	Tablet 250 mg Tablet 500 mg Oral liquid 250 mg/ 5 mL (p) Injection 200 mg/ 100 mL
6.2.2.4	Clarithromycin**	S,T	Tablet 250 mg Tablet 500 mg Oral liquid 125 mg/5 mL (p)
6.2.2.5	Clindamycin***	P,S,T	Capsule 150 mg Capsule 300 mg Injection 150 mg /mL
6.2.2.6	Co-trimoxazole [Sulphamethoxazole (A) + Trimethoprim(B)]****	P,S,T	Tablet 400 mg (A) + 80 mg (B) Tablet 800 mg (A) + 160 mg (B) Oral liquid 200 mg (A) + 40 mg (B)/5 mL (p)

\* Ciprofloxacin formulations are also listed in -

A. **Section 16.2 - Ear, Nose and Throat Medicines,**

B. **Section 21.1.2 - Ophthalmological Medicines- Anti-infective Medicines,**

\*\* Clarithromycin formulations are also listed in **Section 6.4.3 - Anti-infective medicines-Anti-tuberculosis Medicines**

\*\*\*Clindamycin formulations are also listed in -

**A. Section 6.7.5.3 - Anti-infective Medicines- Antiviral Medicines- Medicines for treating Opportunistic Infections in People living with HIV**

**B. Section 6.9.3.1 - Anti-infective Medicines- Drugs for amoebiasis and other parasitic infections - Antipneumocystosis and antitoxoplasmosis medicines**

**C. Section 6.10.1.5 - Anti-infective Medicines- Antimalarial medicines- For curativetreatment**

\*\*\*\* Co-trimoxazole formulations are also listed in **Section 6.9.3.2 - Anti-infective Medicines- Medicines for amoebiasis and other parasitic infections -Antipneumocystosis andantitoxoplasmosis medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.2.2.7	Doxycycline*	P,S,T	Capsule 100 mg Dry Syrup 50 mg/5 mL (p) Power for Injection 100 mg
6.2.2.8	Gentamicin	P,S,T	Injection 10 mg/mL Injection 40 mg/mL
6.2.2.9	Metronidazole**	P,S,T	Tablet 200 mg Tablet 400 mg Oral liquid 200 mg/5 mL (p) Injection 500 mg/100 mL
6.2.2.10	Nitrofurantoin	P,S,T	Tablet 100 mg Oral liquid 25 mg/5 mL (p)
6.2.2.11	Phenoxymethyl penicillin	P,S,T	Tablet 250 mg
6.2.2.12	Procaine Benzylpenicillin	P,S,T	Powder for injection 1000 mg (=1 million IU)
6.2.2.13	Vancomycin	S,T	Capsule 125 mg Capsule 250 mg Powder for Injection 250 mg Powder for Injection 500 mg Powder for Injection 1000 mg

\*Doxycycline formulations are also listed in **Section 6.10.2.1 - Anti-infective Medicines- Antimalarial medicines- For prophylaxis**

\*\*Metronidazole formulations are also listed in **Section 6.9.1.1 - Anti-infective Medicines - Antiprotozoal Medicines - Medicines for amoebiasis and other parasitic infections**

### 6.3 - Antileprosy Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.3.1	Clofazimine*	P,S,T	Capsule 50 mg Capsule 100 mg
6.3.2	Dapsone	P,S,T	Tablet 50 mg

			Tablet 100 mg
6.3.3	Rifampicin**	P,S,T	Capsule 150 mg Capsule 300 mg
<b>6.4-Antituberculosis Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.4.1	Amikacin	S,T	Injection 100 mg/mL Injection 250 mg/mL Injection 500 mg/mL
6.4.2	Bedaquiline	T	Tablet 100 mg
6.4.3	Clarithromycin***	S,T	Tablet 250 mg Tablet 500 mg Tablet 750 mg
*Clofazimine formulations are also listed <b>Section 6.4.5 - Anti-infective Medicines - Anti-tuberculosis medicines</b>			
**Rifampicin formulations are also listed in <b>Section 6.4.15 - Anti-infective Medicines - Anti-tubercular medicine</b>			
***Clarithromycin formulations are also listed in <b>Section 6.2.2.4 - Anti-infective Medicines-Antibacterials -Other Antibacterials</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.4.4	Clofazimine*	S,T	Capsule 50 mg Capsule 100 mg
6.4.5	Cycloserine	S,T	Capsule 125 mg Capsule 250 mg
6.4.6	Delamanid	T	Tablet 50 mg
6.4.7	Ethambutol	P,S,T	Tablet 200 mg Tablet 400 mg Tablet 600 mg Tablet 800 mg
6.4.8	Ethionamide	S,T	Tablet 125 mg Tablet 250 mg
6.4.9	Isoniazid	P,S,T	Tablet 100 mg Tablet 300 mg Oral Liquid 50 mg/5 mL (p)
6.4.10	Levofloxacin	P,S,T	Tablet 250 mg Tablet 500 mg Tablet 750 mg
			Tablet 300 mg

6.4.11	Linezolid	P,S,T	Tablet 600 mg
6.4.12	Moxifloxacin	P,S,T	Tablet 400 mg
<i>*Clofazimine formulations are also listed in Section 6.3.1 - Anti-infective Medicines - Antileprosy medicines</i>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.4.13	Para- aminosalicylic acid	S,T	Granules (As licensed)
6.4.14	Pyrazinamide	P,S,T	Tablet 500 mg Tablet 750 mg Tablet 1000 mg Tablet 1500 mg Oral liquid 250 mg/5 mL (p)
6.4.15	Rifampicin*	P,S,T	Capsule 150 mg Capsule 300 mg Capsule 450 mg Capsule 600 mg Oral liquid 100 mg/ 5 mL (p)
6.4.16	Streptomycin	P,S,T	Powder for Injection 750 mg Powder for Injection 1000 mg
<b>6.5 - Antifungal Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.5.1	Amphotericin B**	S,T	a) Amphotericin B (conventional) - Injection 50mg/vial b) Lipid Amphotericin B - Injection 50 mg/vial c) Liposomal Amphotericin B - Injection 50 mg/vial
<i>*Rifampicin formulations are also listed in Section 6.3.3 - Anti-infective Medicines-Antileprosy medicines</i>			
<i>**Amphotericin B formulations are also listed Section 6.9.2.1 - Anti-infective Medicines Antileishmaniasis medicines</i>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.5.2	Clotrimazole*	P,S,T	Pessary 100 mg
6.5.3	Fluconazole	P,S,T	Tablet 50 mg Tablet 100 mg Tablet 150 mg Tablet 200 mg Tablet 400 mg Oral liquid 50 mg/ 5 mL (p)



		S,T	Injection 200 mg / 100 mL
6.5.4	Griseofulvin	P,S,T	Tablet 125 mg Tablet 250 mg Tablet 375 mg
6.5.5	Itraconazole	S,T	Capsule 100 mg Capsule 200 mg Oral liquid 10 mg/mL
6.5.6	Mupirocin	P,S,T	Ointment 2%
6.5.7	Nystatin	S,T	Pessary 1 Lac IU Oral Liquid 1 Lac IU/mL (p)
6.5.8	Terbinafine	P,S,T	Cream 1%

\*Clotrimazole formulations are also listed in –

**A. Section 6.7.5.4 - Anti-infective Medicines - Antiviral medicines- Medicines for treating Opportunistic Infections in People living with HIV**

**B. Section 11.1.1 - Dermatological Medicines (Topical)- Antifungal medicines**

**C. Section 16.3 - Ear, Nose and Throat Medicines**

## 6.6 - Antiviral Medicines

### 6.6.1 - Antiherpes Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.6.1.1	Acyclovir*	P,S,T	Tablet 200 mg Tablet 400 mg Tablet 800 mg Powder for Injection 250 mg Powder for Injection 500 mg Oral liquid 400 mg/5 mL (p)

### 6.6.2 - Anti-cytomegalovirus (CMV) medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.6.2.1	Valganciclovir**	S, T	Tablet 450 mg Powder for oral solution 50mg / mL

## 6.7- Medicines used in the Management of HIV

### 6.7.1 Nucleoside Reverse Transcriptase Inhibitors

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.7.1.1	Abacavir	S,T	Tablet 60 mg (p) Tablet 300 mg

\*Acyclovir formulations are also listed in -

**A. Section 6.7.5.1 - Anti-infective Medicines - Medicines used in the management of HIV - Medicines for treating Opportunistic Infections in People living with HIV**

**B. Section 21.1.1 - Ophthalmological Medicines- Anti-infective medicine**

**\*\*Valganciclovir formulations are also listed in Section 6.7.5.5 - Anti-infective Medicines- Antiviral medicines - Medicines for treating Opportunistic Infections in People living with HIV**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.7.1.2	Abacavir (A) + Lamivudine (B)	S,T	Tablet 60 mg (A) + 30 mg (B)(p) Tablet 600 mg (A) + 300 mg (B)
6.7.1.3	Lamivudine	S,T	Tablet 100 mg Tablet 150 mg
6.7.1.4	Tenofovir Disproxil Fumarate (TDF)*	S,T	Tablet 300 mg
6.7.1.5	Tenofovir Disproxil Fumarate (A) + Lamivudine (B)	S,T	Tablet 300 mg (A) + 300 mg (B)
6.7.1.6	Tenofovir Disproxil Fumarate (A) + Lamivudine (B) + Dolutegravir (C)	P,S,T	Tablet 300 mg (A) + 300 mg (B) + 50 mg (C)
6.7.1.7	Tenofovir Disproxil Fumarate (A) + Lamivudine (B) + Efavirenz (C)	S,T	Tablet 300 mg (A) + 300 mg (B) + 600 mg (C)
6.7.1.8	Zidovudine	S,T	Tablet 300 mg Oral liquid 50 mg/5 mL (p)
6.7.1.9	Zidovudine (A) + Lamivudine (B)	S,T	Tablet 60 mg (A) + 30 mg (B)(p) Tablet 300 mg (A) + 150 mg (B)

\* Tenofovir Disproxil Fumarate formulations are also listed in **Section 6.8.6 -**

**Anti-infective Medicines- Medicines used in Hepatitis B and Hepatitis C**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.7.1.10	Zidovudine (A) + Lamivudine (B) + Nevirapine (C)	S,T	Tablet 60 mg (A) + 30 mg (B) + 50 mg (C) (p) Tablet 300 mg (A) + 150 mg (B) + 200 mg (C)

**6.7.2 Non-nucleoside Reverse Transcriptase Inhibitors**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.7.2.1	Efavirenz	S,T	Tablet 200 mg (p) Tablet 600 mg

6.7.2.2	Nevirapine	P,S,T	Tablet 200 mg Dispersible Tablet 50 mg (p) Oral liquid 50 mg/ 5 mL (p)
<b>6.7.3 Integrase Inhibitors</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.7.3.1	Dolutegravir	S,T	Tablet 50 mg
6.7.3.2	Raltegravir	S,T	Tablet 400 mg
<b>6.7.4 Protease Inhibitors</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.7.4.1	Atazanavir (A) + Ritonavir (B)	S,T	Tablet 300 mg (A) +Tablet 100 mg (B)
6.7.4.2	Darunavir	S,T	Tablet 600 mg
6.7.4.3	Darunavir (A) +Ritonavir (B)	S,T	Tablet 600 mg (A) +Tablet 100 mg (B)
6.7.4.4	Lopinavir (A) +Ritonavir (B)	S,T	Tablet 100 mg (A) + 25 mg (B) Tablet 200 mg (A) + 50 mg (B) Oral Liquid 80 mg (A) +20 mg (B) /mL (p) Capsule/ Sachet (containing pellets/granules) 40 mg (A) + 10 mg (B) (p)
6.7.4.5	Ritonavir	S,T	Tablet 100 mg
<b>6.7.5 Medicines for treating Opportunistic Infections in People living with HIV</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.7.5.1	Acyclovir*	P,S,T	Injection 250 mg
6.7.5.2	Cefotaxime**	P,S,T	Injection 1000 mg
6.7.5.3	Clindamycin***	P,S,T	Tablet 300 mg
*Acyclovir formulations are also listed in -			
<b>A. Section 6.6.1.1 - Anti-infective Medicines -Antiviral medicines -Anti-herpes medicines</b>			
<b>B. Section 21.1.1 - Ophthalmological Medicines- Anti-infective Medicine</b>			
** Cefotaxime formulations are also listed in <b>Section 6.2.1.9 - Anti-infective Medicines -Antibacterials-Beta-Lactam medicines</b>			
***Clindamycin formulations are also listed in –			
<b>A. Section 6.2.2.5 - Anti-infective Medicines - Antibacterials -Other antibacterials</b>			
<b>B. Section 6.9.3.1 - Anti-infective Medicines - Medicines for amoebiasis and other parasiticinfections - Antipneumocystosis and antitoxoplasmosis medicines</b>			
<b>C. Section 6.10.1.5 - Anti-infective Medicines - Antimalarial medicines- For curative treatment</b>			

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.7.5.4	Clotrimazole*	P,S,T	Ointment 1 %
6.7.5.5	Valganciclovir**	S,T	Tablet/Capsule 450 mg
<b>6.7.6 Additional Medicines for Syndromic Management of Sexually Transmitted Infections</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.7.6.1	Azithromycin***	P,S,T	Tablet 1000 mg
<b>Section 6.8 - Medicines used in Hepatitis B and Hepatitis C</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.8.1	Daclatasvir	S,T	Tablet 30 mg Tablet 60 mg
6.8.2	Entecavir	S,T	Tablet 0.5 mg Tablet 1 mg Oral liquid 0.05 mg/mL (p)
*Clotrimazole formulations are also listed in -			
A. Section 6.5.2 - Anti-infective Medicines - Antifungal medicines			
B. Section 11.1.1 - Dermatological Medicines (Topical)- Antifungal medicines			
C. Section 16.3 - Ear, Nose and Throat Medicines			
**Valganciclovir formulations are also listed in Section 6.6.2.1 - Anti-infective Medicines - Antiviral medicines - Anti Cytomegalovirus (CMV) medicines			
***Azithromycin formulations are also listed in Section 6.2.2.1 - Anti-infective Medicines - Other antibacterials			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.8.3	Ribavirin	S,T	Capsule 200 mg
6.8.4	Sofosbuvir	S,T	Tablet 400 mg
6.8.5	Tenofovir Alafenamide Fumarate (TAF)	S,T	Tablet 25 mg
6.8.6	Tenofovir Disoproxil Fumarate (TDF)*	S,T	Tablet 300 mg
<b>Section 6.9 - Antiprotozoal Medicines</b>			
<b>6.9.1 - Medicines for Amoebiasis and other Parasitic Infections</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.9.1.1	Metronidazole**	P,S,T	Tablet 200 mg Tablet 400 mg Injection 500 mg/100 mL

			Oral liquid 200 mg/5 mL (p)
* <i>Tenofovir Disoproxil Fumarate formulations are also listed in Section 6.7.1.4 -</i>			
<i>Anti-infective Medicines Medicines used in the management of HIV- Nucleoside reverse transcriptase inhibitors</i>			
** <i>Metronidazole formulations are also listed in Section 6.2.2.9 - Anti-infective Medicines -Antibacterials Beta-lactam medicines - Other antibacterials</i>			
<b>6.9.2 - Antileishmaniasis Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.9.2.1	Amphotericin B*	S,T	a) Amphotericin B (conventional)- Injection 50 mg b) Lipid Amphotericin B- Injection 50 mg c) Liposomal Amphotericin B- Injection 50 mg
6.9.2.2	Miltefosine	P,S,T	Capsule 50 mg
6.9.2.3	Paromomycin	P,S,T	Injection 375 mg/mL
<b>6.9.3 - Antipneumocystosis and Antitoxoplasmosis Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.9.3.1	Clindamycin**	P,S,T	Capsule 150 mg Capsule 300 mg
* <i>Amphotericin B formulations are also listed in Section 6.5.1 - Anti-infective Medicines- Antifungal medicines</i>			
** <i>Clindamycin formulations are also listed in -</i>			
<b>A. Section 6.2.2.5 - Anti-infective Medicines - Antibacterials -Other antibacterials</b>			
<b>B. Section 6.7.5.3 - Anti-infective Medicines - Antiviral medicines- Medicines for treating Opportunistic Infections in People living with HIV</b>			
<b>C. Section 6.10.1.5 - Anti-infective Medicines- Antimalarial Medicines - For curativetreatment</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.9.3.2	Co-trimoxazole* [Sulphamethoxazole (A) + Trimethoprim (B)]	P,S,T	Tablet 400 mg (A) + 80 mg (B) Tablet 800 mg (A) + 160 mg (B) Oral liquid 200 mg (A) + 40 mg (B)/5 mL (p)
<b>6.10-Antimalarial Medicines</b>			
<b>6.10.1 - For curative treatment</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
6.10.1.1	Artemether (A) + Lumefantrine (B)	P,S,T	Tablet 20 mg (A) + 120 mg (B) Tablet 40 mg (A) + 240 mg (B) Tablet 80 mg (A) + 480 mg (B)

6.10.1.2	Artesunate	P,S,T	Powder for Injection 60 mg Powder for Injection 120 mg
6.10.1.3	Artesunate (A) + Sulphadoxine Pyrimethamine (B)	P,S,T	Combi pack (A+B) 1 Tablet 25 mg (A) + 1 Tablet (250 mg + 12.5 mg) (B) 1 Tablet 50 mg (A) + 1 Tablet (500 mg + 25 mg) (B) 1 Tablet 100 mg (A) + 1 Tablet (750 mg + 37.5 mg) (B) 1 Tablet 150 mg (A) + 2 Tablet (500 mg + 25 mg) (B) 1 Tablet 200 mg (A) + 2 Tablet (750 mg + 37.5 mg) (B)

\*Co-trimoxazole formulations are also listed in **Section 6.2.2.6 - Anti-infective Medicines-Antibacterials - Other antibacterials**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.10.1.4	Chloroquine	P,S,T	Tablet 150 mg Oral liquid 50 mg/5 mL
6.10.1.5	Clindamycin*	P,S,T	Capsule 150 mg Capsule 300 mg
6.10.1.6	Primaquine	P,S,T	Tablet 2.5 mg Tablet 7.5 mg Tablet 15 mg
6.10.1.7	Quinine	P,S,T	Tablet 300 mg Injection 300 mg/mL

#### 6.10.2 - For prophylaxis

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
6.10.2.1	Doxycycline**#	P,S,T	Capsule 100 mg Oral liquid 50 mg/ 5mL #for prophylaxis of <i>P. vivax</i>
6.10.2.2	Mefloquine#	T	Tablet 250 mg #Only for use as chemoprophylaxis for long term travellers like military and travel troops, travelling from low endemic to high endemic area.

\* Clindamycin formulations are also listed in -

**A. Section 6.2.2.5 - Anti-infective Medicines - Antibacterials -Other antibacterials**

**B. Section 6.7.5.3 - Anti-infective Medicines - Antiviral medicines- Medicines for treating Opportunistic Infections in People living with HIV**

**C. Section 6.9.3.1 - Anti-infective Medicines - Antipneumocystosis and antitoxoplasmosismedicines**

**\*\* Doxycycline formulations are also listed in Section 6.2.2.7 - Anti-infective Medicines-Antibacterials - Other antibacterials**

### Section 7

#### Anti-cancer agents including Immunosuppressives and Medicines used in Palliative Care

#### 7.1 - Antineoplastic medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
7.1.1	5-Fluorouracil	T	Injection 250 mg/ 5 mL
7.1.2	6-Mercaptopurine	T	Tablet 50 mg
7.1.3	Actinomycin D	T	Powder for Injection 0.5 mg
7.1.4	All-trans retinoic acid	T	Capsule 10 mg
7.1.5	Arsenic trioxide	T	Injection 1mg/ mL
7.1.6	Bendamustinehydrochloride	T	Injection 25 mg/ vial Injection 100 mg/vial
7.1.7	Bleomycin	T	Powder for Injection 15 units
7.1.8	Bortezomib	T	Powder for Injection 2 mg
7.1.9	Calcium folinate	T	Tablet 15 mg Injection 3 mg/mL
7.1.10	Capecitabine	T	Tablet 500 mg
7.1.11	Carboplatin	T	Injection 10 mg/mL
7.1.12	Chlorambucil	T	Tablet 2 mg Tablet 5 mg
7.1.13	Cisplatin	T	Injection 1mg/mL
7.1.14	Cyclophosphamide	T	Tablet 50 mg Powder for Injection 500 mg
7.1.15	Cytosine arabinoside	T	Injection 100 mg/vial Injection 500 mg/vial Injection 1000 mg/vial
7.1.16	Dacarbazine	T	Powder for Injection 200 mg Powder for Injection 500 mg
7.1.17	Daunorubicin	T	Injection 5 mg/mL
7.1.18	Docetaxel	T	Powder for Injection 20 mg Powder for Injection 80 mg
7.1.19	Doxorubicin	T	Injection 2 mg/mL
7.1.20	Etoposide	T	Capsule 50 mg

			Injection 20 mg/mL
7.1.21	Gefitinib	T	Tablet 250 mg
7.1.22	Gemcitabine	T	Powder for Injection 200 mg Powder for Injection 1000 mg
7.1.23	Hydroxyurea*	T	Capsule 500 mg
7.1.24	Ifosfamide	T	Powder for Injection 1000 mg Powder for Injection 2000 mg
7.1.25	Imatinib	T	Tablet 100 mg Tablet 400 mg
7.1.26	Irinotecan HCl trihydrate	T	Solution for injection 20 mg/ mL
7.1.27	L-Asparaginase	T	Powder for Injection 5000 KU Powder for Injection 10000 KU
7.1.28	Lenalidomide	T	Capsule 5 mg Capsule 25 mg
7.1.29	Melphalan	T	Tablet 2 mg Tablet 5 mg
7.1.30	Methotrexate**	S,T	Tablet 2.5 mg Tablet 5 mg Tablet 10 mg Injection 50 mg/mL

\*Hydroxyurea formulations are also listed in **Section 8.1.6 - Medicines affecting Blood- Antianaemia Medicines**

\*\*Methotrexate formulations are also listed in **Section 2.4.3 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Disease Modifying Agents used in Rheumatoid Disorders**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
7.1.31	Oxaliplatin	T	Injection 5 mg/mL in 10 mL vial Injection 5 mg/mL in 20 mL vial
7.1.32	Paclitaxel	T	Injection 30 mg/5 mL Injection 100 mg/16.7 mL
7.1.33	Rituximab	T	Injection 10 mg/mL
7.1.34	Temozolomide	T	Capsule 20 mg Capsule 100 mg Capsule 250 mg
7.1.35	Thalidomide	T	Capsule 50 mg Capsule 100 mg
7.1.36	Trastuzumab	T	Injection 440 mg/50 mL
7.1.37	Vinblastine	T	Injection 1 mg/mL
7.1.38	Vincristine	T	Injection 1 mg/mL



**7.2-Hormones and Anti-hormones used in Cancer Therapy**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
7.2.1	Bicalutamide	T	Tablet 50 mg
7.2.2	Letrozole	T	Tablet 2.5 mg
7.2.3	Leuprolide acetate	T	Powder for injection 3.75 mg Powder for injection 11.25 mg Powder for injection 22.5 mg
7.2.4	Prednisolone*	S,T	Tablet 10 mg Tablet 20 mg Tablet 40 mg Oral liquid 5 mg/5 mL (p) Oral liquid 15 mg/5 mL (p) Injection 20 mg/2 mL
7.2.5	Tamoxifen	T	Tablet 10 mg Tablet 20 mg

**7.3 - Immunosuppressive Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
7.3.1	Azathioprine**	T	Tablet 50 mg
7.3.2	Cyclosporine	T	Capsule 25 mg Capsule 50 mg Capsule 100 mg Oral liquid 100 mg/mL (p) Injection 50 mg/mL

\*Prednisolone formulations are also listed in -

**A. Section 3.6 - Antiallergics and Medicines used in Anaphylaxis**

**B. Section 18.1.5 - Hormones, other Endocrine Medicines and Contraceptives -Adrenal Hormones and synthetic substitutes**

**C. Section 21.2.1 - Ophthalmological Medicines - Antiinflammatory Medicine**

\*\*Azathioprine formulations are also listed in **Section 2.4.1 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Disease Modifying Agents used in Rheumatoid Disorders**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
7.3.3	Mycophenolate mofetil	T	Tablet 250 mg Tablet 500 mg
7.3.4	Tacrolimus	T	Capsule 0.5 mg Capsule 1 mg

			Capsule 2 mg
<b>7.4-Medicines used in Palliative Care</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
7.4.1	Allopurinol*	S,T	Tablet 100 mg
7.4.2	Amitriptyline**	S,T	Tablet 10 mg Tablet 25 mg
7.4.3	Dexamethasone***	S,T	Tablet 0.5 mg Tablet 4 mg Injection 4 mg/mL
<p>*Allopurinol formulations are also listed in <b>Section 2.3.1</b> - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Medicines used to treat Gout</p> <p>**Amitriptyline formulations are also listed in <b>A. Section 5.2.5</b> - Medicines used in Neurological Disorders - Anti-migraine medicines - For prophylaxis</p> <p><b>B. Section 23.2.1.1</b> - Medicines in treatment of Psychiatric Disorders - Medicines used in mood disorders- Medicines used in depressive disorders</p> <p>***Dexamethasone formulations are also listed in</p> <p><b>A. Section 3.4</b> - Antiallergics and medicines used in anaphylaxis</p> <p><b>B. Section 18.1.1</b> - Hormones, other Endocrine Medicines and Contraceptives - Adrenal hormones and synthetic substitutes</p> <p><b>C. Section 27.1</b> - Medicines for COVID- 19 management</p>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
7.4.4	Diazepam*	S,T	Tablet 2 mg Tablet 5 mg Injection 5 mg/mL
7.4.5	Filgrastim	T	Injection 300 mcg
7.4.6	Fluoxetine**	S,T	Capsule 20 mg
7.4.7	Haloperidol***	S,T	Tablet 1.5 mg Tablet 5 mg Injection 5 mg/mL
7.4.8	Lactulose****	S,T	Oral liquid 10 g/15 mL
7.4.9	Loperamide	S,T	Tablet 2 mg
<p>*Diazepam formulations are also listed <b>Section 5.1.3</b> - Medicines used in Neurological Disorders - Anticonvulsants/Antiepileptics</p> <p>**Fluoxetine formulations are also listed in</p> <p><b>A. Section 23.2.1.3</b> - Medicines in used in treatment of Psychiatric Disorders - Medicines used in mood disorders - Medicines used in depressive disorders</p>			

**B. Section 23.4.2 - Medicines used in treatment of Psychiatric Disorders - Medicines used in obsessive compulsive disorders and panic attacks**

\*\*\*Haloperidol formulations are also listed in **Section 23.1.3 -**

Medicines used in treatment of psychiatric Disorders - Medicines used in psychotic disorders

\*\*\*\*Lactulose formulations are also listed in **Section 17.5.3 -**

Gastrointestinal Medicines - Laxatives

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
7.4.10	Metoclopramide*	S,T	Tablet 10 mg Oral liquid 5 mg/5 mL (p) Injection 5 mg/mL
7.4.11	Mesna	T	Injection 100 mg/mL
7.4.12	Midazolam**	S,T	Injection 1 mg/mL
7.4.13	Morphine***	S,T	Tablet 10 mg Modified Release Tablet 30 mg
7.4.14	Ondansetron****	S,T	Tablet 4 mg Tablet 8 mg Oral liquid 2 mg/5 mL (p) Injection 2 mg/mL

Metoclopramide formulations are also listed in **Section 17.2.2 -**

Gastrointestinal Medicines Antiemetics

\*\*Midazolam formulations are also listed in -

**A. Section 1.3.3 - Medicines used in Anaesthesia - Preoperative medication and sedation for short term procedures**

**B. Section 5.1.7 - Medicines used in Neurological Disorders -Anticonvulsants/Antiepileptics**

\*\*\*Morphine formulations are also listed in -

**A. Section 1.3.4 - Medicines used in Anaesthesia - Preoperative medication and sedation for short term procedures**

**B. Section 2.2.2 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Opioid Analgesics**

\*\*\*\*Ondansetron formulations are also listed **Section 17.2.3 - Gastrointestinal Medicines - anti-ulcer medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
7.4.15	Tramadol*	S,T	Capsule 50 mg Capsule 100 mg Injection 50 mg/mL
7.4.16	Zoledronic acid	T	Powder for Injection 4 mg

<b>Section 8</b>			
<b>Medicines affecting Blood</b>			
<b>8.1- Antianaemia Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
8.1.1	Erythropoietin	S,T	Injection 2000 IU/mL Injection 10000 IU/mL
8.1.2	Ferrous salts (a) Iron Dextran (b) Iron sorbitol citrate complex	P,S,T	Tablet equivalent to 60 mg of elemental iron Injection 50 mg/mL Injection 50 mg/mL
8.1.3	Ferrous Salt (A)+ Folic acid (B)	P,S,T	Tablet 45 mg elemental iron (A) + 400 mcg (B) Tablet 100 mg elemental iron (A) + 500 mcg (B) Oral liquid 20 mg elemental iron (A) + 100 mcg/mL (B) (p)
<i>*Tramadol formulations are also listed in Section 2.2.3 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and disease Modifying agents used in Rheumatoid Disorders- Opioid Analgesics</i>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
8.1.4	Folic Acid	P,S,T	Tablet 1 mg Tablet 5 mg
8.1.5	Hydroxocobalamin	P,S,T	Injection 1 mg/mL
8.1.6	Hydroxyurea*	S,T	Capsule 500 mg
8.1.7	Iron sucrose	S,T	Injection 20 mg/mL
<b>8.2 - Medicines affecting Coagulation</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
8.2.1	Enoxaparin**	S,T	Injection 40 mg/ 0.4 mL Injection 60 mg/ 0.6 mL
8.2.2	Heparin***	S,T	Injection 1000 IU/mL Injection 5000 IU/mL
8.2.3	Phytomenadione(Vitamin K <sub>1</sub> )	P,S,T	Tablet 10 mg Injection 10 mg/mL
8.2.4	Protamine Sulphate	S,T	Injection 10 mg/mL
8.2.5	Tranexamic acid	P,S,T	Tablet 500 mg Injection 100 mg/mL

\* *Hydroxyurea formulations are also listed in Section 7.1.26 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care- Antineoplastic medicines*

\*\* *Enoxaparin formulations are also listed in*

A. **Section 10.5.4 - Cardiovascular Medicines - Antiplatelet and Antithrombotic Medicines**

B. **Section 27.2 - Medicines for COVID- 19 management**

\*\*\* *Heparin formulations are also listed in Section 10.5.5 - Cardiovascular Medicines -Antiplatelet and Antithrombotic Medicines*

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
8.2.6	Warfarin	S,T	Tablet 1 mg Tablet 2 mg Tablet 3 mg Tablet 5 mg

### Section 9

#### Blood products and Plasma substitutes

#### 9.1 - Blood and Blood components

All forms of the following as approved by licensing authority are considered as included in NLEM. However, considering the process, technology and other relevant aspects, they should be considered differently for purposes such as procurement policy, pricing etc.

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
9.1.1	Fresh frozen plasma	S,T	As licensed
9.1.2	Platelet rich plasma/ Platelet concentrates	S,T	As licensed
9.1.3	Red blood cells/Packed RBCs	S,T	As licensed
9.1.4	Whole blood	S,T	As licensed

#### 9.2 - Plasma substitutes

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
9.2.1	Dextran-40	S,T	Injection 10 %

#### 9.3 - Plasma fractions for specific use

In case of coagulation factors and other blood products, irrespective of variation in source, all forms of these products as approved by licensing authority are considered as included in NLEM. However, considering the source, process, technology and other relevant aspects, they should be considered differently for purposes such as procurement policy, pricing etc.

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
9.3.1	Coagulation factor IX	S,T	Powder for Injection 600 IU
9.3.2	Coagulation factor VIII	S,T	Powder for Injection 250 IU Powder for Injection 500 IU

9.3.3	Cryoprecipitate	S,T	As licensed
<b>Section 10</b>			
<b>Cardiovascular Medicines</b>			
<b>10.1-Medicines used in Angina</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
10.1.1	Diltiazem	P,S,T	Tablet 30 mg Tablet 60 mg Modified Release Tablet 180 mg
		S, T	Injection 5 mg/mL
10.1.2	Glyceryl trinitrate	P,S,T	Sublingual Tablet 0.5 mg
		S,T	Injection 5 mg/mL
10.1.3	Isosorbide dinitrate	P,S,T	Tablet 5 mg Tablet 10 mg
10.1.4	Metoprolol	P,S,T	Tablet 25 mg Tablet 50 mg Tablet 100 mg Modified Release Tablet 100 mg
		S,T	Injection 1 mg/mL
<b>10.2 - Antiarrhythmic medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
10.2.1	Adenosine	S,T	Injection 3 mg/mL
10.2.2	Amiodarone	S,T	Tablet 100 mg Tablet 200 mg Injection 50 mg/mL
10.2.3	Digoxin*	S,T	Tablet 0.25 mg Oral liquid 0.05 mg/mL Injection 0.25 mg/mL
10.2.4	Esmolol	S,T	Injection 10 mg/mL
10.2.5	Lignocaine**	S,T	Injection 2%
10.2.6	Verapamil	S,T	Tablet 40 mg Tablet 80 mg Injection 2.5 mg/ mL
<b>10.3 - Antihypertensive Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
10.3.1	Amlodipine	P,S,T	Tablet 2.5 mg Tablet 5 mg Tablet 10 mg

*\*Digoxin formulations are also listed in Section 10.4.1 - Cardiovascular Medicines -*

*Medicines used in Shock and Heart Failure*

*\*\*Lignocaine formulations are also listed in Section 1.2.2 - Medicines used in Anaesthesia - Local Anaesthetics*

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
10.3.2	Enalapril	P,S,T	Tablet 2.5 mg Tablet 5 mg
10.3.3	Hydrochlorothiazide*	P,S,T	Tablet 12.5 mg Tablet 25 mg
10.3.4	Labetalol	P,S,T	Tablet 50 mg Tablet 100 mg
		P,S,T	Injection 5 mg/mL
10.3.5	Ramipril	P,S,T	Tablet 2.5 mg Tablet 5 mg
10.3.6	Sodium nitroprusside	S, T	Injection 10 mg/mL
10.3.7	Telmisartan	P,S,T	Tablet 20 mg Tablet 40 mg Tablet 80 mg

#### 10.4 - Medicines used in Shock and Heart failure

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
10.4.1	Digoxin**	S,T	Tablet 0.25 mg Oral liquid 0.05 mg/mL Injection 0.25 mg/mL

*\*Hydrochlorothiazide formulations are also listed in Section 15.2 - Diuretics*

*\*\*Digoxin formulations are also listed in Section 10.2.3 - Cardiovascular Medicines - Antiarrhythmic medicines*

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
10.4.2	Dobutamine	S,T	Injection 50 mg/mL
10.4.3	Dopamine	S,T	Injection 40 mg/mL
10.4.4	Noradrenaline	S,T	Injection 2 mg/mL
10.4.5	Spironolactone*	P,S,T	Tablet 25 mg
			Tablet 50 mg

#### 10.5- Antiplatelet and Antithrombotic Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
10.5.1	Acetylsalicylic acid**	P,S,T	Conventional/Effervescent/Dispersible/ Enteric coated Tablets 150 mg
			Conventional/Effervescent/Dispersible/ Enteric coated Tablets 325 mg
			Enteric coated Tablet 75 mg Enteric coated Tablet 100 mg

\**Spirolactone formulations are also listed in Section 15.4 - Diuretics*

\*\**Acetylsalicylic acid formulations are also listed in -*

A. **Section 2.1.1 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory**

*Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Non-opioid Analgesics, Antipyretics and Non-steroidal Anti-inflammatory Drugs*

B. **Section 5.2.1 - Medicines used in Neurological Disorders- Antimigraine medicines**

10.5.2	Clopidogrel	P,S,T	Tablet 75 mg Tablet 150 mg
10.5.3	Dabigatran	S, T	Tablet 110 mg Tablet 150 mg
10.5.4	Enoxaparin*	S,T	Injection 40 mg/ 0.4 mL Injection 60 mg/ 0.6 mL
10.5.5	Heparin**	S,T	Injection 1000 IU/mL Injection 5000 IU/mL
10.5.6	Streptokinase	S,T	Injection 750,000 IU Injection 15,00,000 IU
10.5.7	Tenecteplase	S,T	Injection 30 mg/vial Injection 40 mg/vial

### 10.6 - Hypolipidemic Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
10.6.1	Atorvastatin	P,S,T	Tablet 10 mg Tablet 20 mg Tablet 40 mg Tablet 80 mg

\**Enoxaparin formulations are also listed in -*

A. **Section 8.2.1 - Medicines affecting Blood - Medicines affecting coagulation**

B. **Section 27.2 - Medicines for COVID- 19 management**

\*\**Heparin formulations are also listed in Section 8.2.2 - Medicines affecting Blood - Medicines affecting coagulation*

### Section 11

#### Dermatological Medicines (Topical)

#### 11.1 - Antifungal Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
11.1.1	Clotrimazole*	P,S,T	Cream 1 % Lotion 1 %

#### 11.2 - Antibacterial Medicines



	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
11.2.1	Framycetin	P,S,T	Cream 1 %
11.2.2	Fusidic acid	P,S,T	Cream 2 %
11.2.3	Silver sulphadiazine	P,S,T	Cream 1 %
<b>11.3-Anti-inflammatory and Antipruritic Medicines</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
11.3.1	Betamethasone valerate	P,S,T	Cream 0.05 % Cream 0.1 %
<i>*Clotrimazole formulations are also listed in -</i>			
<b>A. Section 6.5.2 - Anti-infective Medicines -Antifungal medicines</b>			
<b>B. Section 6.7.5.4 - Anti-infective Medicines - Antiviral medicines- Medicines used in themanagement of HIV</b>			
<b>C. Section 16.3 - Ear, Nose and Throat Medicines</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
11.3.2	Calamine	P,S,T	Lotion (As per IP)
<b>11.4 - Keratolytic agents</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
11.4.1	Benzoyl peroxide	P,S,T	Gel 2.5 % - 5 %
11.4.2	Coal tar (A) + Salicylic Acid (B)	P,S,T	Solution 1 % (A) + 3 % (B)
11.4.3	Podophyllin resin	S,T	Solution 20 %
11.4.4	Salicylic acid	P,S,T	Ointment 3-6 %
<b>11.5 - Scabicides and Pediculicides</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
11.5.1	Permethrin	P,S,T	Lotion 1 % Cream 5 %
<b>11.6 Miscellaneous</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
11.6.1	Glycerin/glycerol mentioned in IP)	(as P,S,T	Topical
<b>Section 12</b>			
<b>Diagnostic agents</b>			
<b>12.1 - Ophthalmic Medicines</b>			
	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
12.1.1	Fluorescein	S,T	Ophthalmic Strips
12.1.2	Proparacaine*	S,T	Eye Drops 0.5%

12.1.3	Tropicamide**	S,T	Eye drop 1 %
<b>12.2 - Radiocontrast Media</b>			
12.2.1	Barium sulphate	S,T	Oral Liquid 95% w/v
12.2.2	Gadobenate dimeglumine	T	Injection 529 mg/mL
12.2.3	Iohexol	S,T	Injection 140 to 350 mg iodine/mL
12.2.4	Meglumine diatrizoate	S,T	Injection 60 % w/v Injection 76 % w/v
* <i>Proparacaine formulations are also listed in Section 21.3.1 - Ophthalmological Medicines- Local Anaesthetics</i>			
** <i>Tropicamide formulations are also listed in Section 21.5.4 - Ophthalmological Medicines - Mydriatics</i>			
<b>Section 13</b>			
<b>Dialysis components (Haemodialysis and Peritoneal Dialysis)</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>of Dosage form(s) and strength(s)</b>
13.1	Haemodialysis fluid	S,T	As licensed
13.2	Peritoneal dialysis solution	S,T	As licensed
<b>Section 14</b>			
<b>Antiseptics and Disinfectants</b>			
<b>14.1 Antiseptics</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
14.1.1	Chlorhexidine	P,S,T	Solution 5% (Concentrate)
14.1.2	Ethyl alcohol(Denatured)	P,S,T	Solution 70%
14.1.3	Hydrogen peroxide	P,S,T	Solution 6 %
14.1.4	Methylrosaniliniumchloride (Gentian Violet)	P,S,T	Topical preparation 0.25% to 2%
14.1.5	Povidone iodine*	P,S,T	Solution 4 % to 10 %
* <i>Povidone Iodine formulations are also listed in Section 21.1.5 - Ophthalmological Medicines - Anti-infective medicine</i>			
<b>14.2 Disinfectants</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
14.2.1	Glutaraldehyde	S,T	As Licensed
14.2.2	Potassium permanganate	P,S,T	Crystals for topicalsolution
<b>Section 15</b>			
<b>Diuretics</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
15.1	Furosemide	P,S,T	Tablet 40 mg Oral liquid 10 mg/mL

			Injection 10 mg/ mL
15.2	Hydrochlorothiazide *	P,S,T	Tablet 25 mg Tablet 50 mg
15.3	Mannitol	P,S,T	Injection 10 % Injection 20 %
15.4	Spirolactone**	P,S,T	Tablet 25 mg Tablet 50 mg

\* Hydrochlorothiazide formulations are also listed in **Section 10.3.3 - Antihypertensive Medicines**

\*\*Spirolactone formulations are also listed in **Section 10.4.5 - Cardiovascular Medicines - Medicines used in shock and heart failure**

### Section 16

#### Ear, Nose and Throat Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
16.1	Budesonide*	P,S,T	Nasal Spray 50 mcg/dose Nasal Spray 100 mcg/dose
16.2	Ciprofloxacin**	P,S,T	Drops 0.3 %
16.3	Clotrimazole***	P,S,T	Drops 1 %
16.4	Xylometazoline	P,S,T	Nasal drops 0.05 % Nasal drops 0.1 %

\*Budesonide formulations are also listed in **Section 24.1 - Medicines acting on the respiratory tract - Antiasthmatic Medicines**

\*\*Ciprofloxacin formulations are also listed in

**A. Section 6.2.2.3 - Anti-infective Medicines- Antibacterials -Other Antibacterials**

**B. Section 21.1.2 - Ophthalmological Medicines- Anti-infective Medicines**

\*\*\*Clotrimazole formulations are also listed in -

**A. Section 6.5.2 - Anti-infective Medicines -Antifungal medicines**

**B. Section 6.7.5.4 - Anti-infective Medicines - Antiviral medicines- Medicines used in the management of HIV**

**C. Section 11.1.1 - Dermatological Medicines (Topical) -Antifungal medicines**

### Section 17

#### Gastrointestinal Medicines

#### 17.1 - Antiulcer Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
17.1.1	Omeprazole	P,S,T	Capsule 10 mg Capsule 20 mg Capsule 40 mg Powder for oral liquid 20 mg

17.1.2	Pantoprazole	S,T	Injection 40 mg
<b>17.2 Antiemetics</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
17.2.1	Domperidone	P,S,T	Tablet 10 mg Oral Liquid 1 mg/mL
17.2.2	Metoclopramide*	P,S,T	Tablet 10 mg Injection 5 mg/mL
17.2.3	Ondansetron*	S,T	Tablet 4 mg Oral Liquid 2 mg/5 mL (p) Injection 2 mg/ mL
*Metoclopramide formulations are also listed in <b>Section 7.4.10</b> - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care			
*Ondansetron formulations are also listed in <b>Section 7.4.14</b> - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care			
<b>17.3 Anti-inflammatory medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
17.3.1	5-aminosalicylic acid (Mesalazine/ Mesalaine)	S, T	Tablet 400 mg Suppository 500 mg Retention Enema
<b>17.4 Antispasmodic medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
17.4.1	Dicyclomine	P,S,T	Tablet 10 mg Oral Solution 10 mg/5mL Injection 10 mg/ mL
17.4.2	Hyoscine butyl bromide	P,S,T	Tablet 100 mg Injection 20 mg/ mL
<b>17.5 Laxatives</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
17.5.1	Bisacodyl	P,S,T	Tablet 5 mg Suppository 5 mg
17.5.2	Ispaghula	P,S,T	Granules/ Husk/ Powder
17.5.3	Lactulose*	S,T	Oral Liquid 10 g/15 mL

<b>17.6 Medicines used in diarrhea</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
17.6.1	Oral rehydrationsalts**	P,S,T	As licensed
17.6.2	Zinc Sulphate	P,S,T	Dispersible Tablet 20 mg
<b>17.7 Other medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
17.7.1	Somatostatin	T	Powder for Injection 3 mg
*Lactulose formulations are also listed in <b>Section 7.4.8 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in PalliativeCare</b>			
**Oral rehydration salts formulations are also listed in <b>Section 25.3 - Solutions correcting water, electrolyte disturbances and acid-base disturbances</b>			
<b>Section 18</b>			
<b>Hormones, other Endocrine Medicines and Contraceptives</b>			
<b>18.1-Adrenal Hormones and Synthetic substitutes</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
18.1.1	Dexamethasone*	S,T	Tablet 0.5 mg Injection 4 mg/mL
18.1.2	Fludrocortisone	S,T	Tablet 0.1 mg
18.1.3	Hydrocortisone**	P,S,T	Tablet 5 mg Tablet 10 mg Tablet 20 mg Powder for Injection 100 mg
18.1.4	Methylprednisolone ***	S,T	Injection 40mg/mL
*Dexamethasone formulations are also listed in –			
<b>A. Section 3.4 - Antiallergics and Medicines used in Anaphylaxis</b>			
<b>B. Section 7.4.3 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care</b>			
<b>C. Section 27.1 - Medicines for COVID- 19 Management</b>			
** Hydrocortisone formulations are also listed in <b>Section 3.5 - Antiallergics and Medicines used in Anaphylaxis</b>			
*** Methylprednisolone formulations are also listed in <b>section 27.3- Medicines for COVID - 19 management</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
			Tablet 5 mg Tablet 10 mg

18.1.5	Prednisolone*	P,S,T	Tablet 20 mg Oral liquid 5 mg/5 mL (p) Oral liquid 15 mg/5 mL (p)
<b>18.2 Contraceptives</b>			
<b>18.2.1 - Hormonal Contraceptives</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
18.2.1.1	Ethinylestradiol (A)+ Levonorgestrel (B)	P,S,T	Tablet 0.03 mg (A) +Tablet 0.15 mg (B)
18.2.1.2	Levonorgestrel	P,S,T	Tablet 0.75 mg Tablet 1.5 mg
18.2.1.3	Ormeloxifene (Centchroman)	P,S,T	Tablet 30 mg
<i>*Prednisolone formulations are also listed in -</i>			
<b>A. Section 3.7 - Antiallergics and Medicines used in Anaphylaxis</b>			
<b>B. Section 7.2.4 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care Hormones and anti- hormones used in cancer therapy</b>			
<b>C. Section 21.2.1 - Ophthalmological Medicines – Anti-inflammatory medicine</b>			
<b>18.2.2 - Intrauterine Devices</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
18.2.2.1	Hormone releasing IUD	T	Contains 52 mg of Levonorgestrel
18.2.2.2	IUD containing Copper	P,S,T	As licensed
<b>18.2.3 - Barrier methods</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
18.2.3.1	Condom	P,S,T	As Licensed-as per the standards of Drugs Rules, 1945
<b>18.3 - Medicines used in Diabetes Mellitus</b>			
<b>18.3.1 - Insulins and other Antidiabetic agents</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
18.3.1.1	Glimepiride	P,S,T	Tablet 1 mg Tablet 2 mg
18.3.1.2	Insulin (Soluble)	P,S,T	Injection 40 IU/mL
18.3.1.3	Insulin Intermediate Acting (NPH)	P,S,T	Injection 40 IU/mL
18.3.1.4	Insulin Glargine	P,S,T	Injection 100 IU/mL
18.3.1.5	Insulin Premix Injection 30:70 (Regular : NPH)	P,S,T	Injection 40 IU/mL

18.3.1.6	Metformin	P,S,T	Tablet 500 mg Tablet 1000 mg Modified release Tablet 1000 mg
18.3.1.7	Teneligliptin	P,S,T	Tablet 20 mg

**18.3.2 - Medicines used to treat Hypoglycemia**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
18.3.2.1	Glucose*	P,S,T	Injection 25 %

**18.4-Ovulation Inducers**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
18.4.1	Clomiphene citrate	T	Tablet 50 mg Tablet 100 mg
18.4.2	Human chorionic gonadotropin	S,T	Injection 2000 IU Injection 5000 IU Injection 10000 IU

\*Glucose formulations are also listed in **Section 25.1 - Solutions correcting water, electrolyte disturbances and acid-base disturbances**

**18.5-Progestogens**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
18.5.1	Medroxyprogesterone acetate	P,S,T	Tablet 5 mg Tablet 10 mg Injection 150 mg/ mL
18.5.2	Norethisterone	P,S,T	Tablet 5 mg

**18.6-Thyroid and Antithyroid Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
18.6.1	Carbimazole	P,S,T	Tablet 5 mg Tablet 10 mg Tablet 20 mg
18.6.2	Levothyroxine	P,S,T	Tablet 12.5 mcg to 150 mcg* (*Several strengths are available in market such as 12.5,25,50,62.5, 75, 88,100, 112mcg. Therefore, it was considered to give a range of available strengths)

**Section 19****Immunologicals**

In case of these biologicals, irrespective of variation in source, composition and strengths, all the products of the same vaccine/ sera/ immunoglobulin, as approved by licensing authority are considered as included in NLEM. However, considering the source, process, technology and other relevant aspects, different products of the same biological should be considered differently for purposes such as procurement policy, pricing etc.

<b>19.1-Diagnostic agents</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
19.1.1	Tuberculin, Purified Protein derivative	P,S,T	As Licensed
<b>19.2-Sera and Immunoglobulins (Liquid/ Lyophilized)</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
19.2.1	Anti-rabies immunoglobulin	P,S,T	As Licensed
19.2.2	Anti-tetanus immunoglobulin	P,S,T	As Licensed
19.2.3	Anti-D immunoglobulin	S,T	As Licensed
19.2.4	Diphtheria antitoxin	P,S,T	As Licensed
19.2.5	Hepatitis B immunoglobulin	S,T	As Licensed
19.2.6	Human normal immunoglobulin	T	As Licensed
19.2.7	Snake Venom Antiserum*	P,S,T	a) Soluble/ liquid polyvalent - As Licensed b) Lyophilized polyvalent - As Licensed
*Snake Venom antiserum also listed in <b>Section 4.2.12 - Antidotes and Other Substances used in Management of Poisonings/Envenomation - Specific</b>			
<b>19.3-Vaccines</b>			
a) All the vaccines which are under Universal Immunization Program of India (UIP) will be deemed included in NLEM. Presently, the UIP has BCG, DPT, OPV, measles, Hepatitis B, Japanese encephalitis, Pentavalent Vaccines and Rota virus vaccine.			
b) The vaccines, which have been approved by National Technical Advisory Group on Immunization (NTAGI) and planned to be given under UIP, will be deemed to be included as and when listed in UIP. These vaccines are inactivated polio vaccine (IPV) and Measles Rubella (MR).			
c) In future, the vaccines which are under consideration, if and when included in UIP, will also be deemed included from the date of inclusion in UIP. These are pneumococcal and HPV vaccines.			
<b>For Universal Immunization</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
19.3.1	BCG vaccine	P,S,T	As licensed
19.3.2	DPT+ Hib+ HepB vaccine	P,S,T	As licensed
19.3.3	DPT vaccine	P,S,T	As licensed
19.3.4	Hepatitis B vaccine	P,S,T	As licensed
19.3.5	Japanese encephalitis vaccine	P,S,T	As licensed



19.3.6	Measles vaccine	P,S,T	As licensed
19.3.7	Oral poliomyelitisvaccine	P,S,T	As licensed
19.3.8	Rotavirus vaccine	P,S,T	As licensed
19.3.9	Tetanus toxoid	P,S,T	As licensed

**19.4 - For Specific Group of Individuals**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
19.4.1	Rabies vaccine	P,S,T	As licensed

**Section 20****Medicines for Neonatal Care**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
20.1	Alprostadiol	S,T	Injection 0.5 mg/mL
20.2	Caffeine	S,T	Oral liquid 20 mg/mL Injection 20 mg/mL
20.3	Surfactant	S,T	Suspension for intratracheal instillation (As licensed)

**Section 21****Ophthalmological Medicines****21.1-Anti-infective Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
21.1.1	Acyclovir*	P,S,T	Ointment 3%
21.1.2	Ciprofloxacin**	P,S,T	Drops 0.3% Ointment 0.3%
21.1.3	Natamycin	P,S,T	Drops 5 %
21.1.4	Povidone iodine***	P,S,T	Drops 5 %

**21.2-Anti-inflammatory Medicine**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
21.2.1	Prednisolone****	P,S,T	Drops 1 %

\*Acyclovir formulations are also listed in -

**A.** Anti-infective Medicines -Antiviral medicines -Anti-herpes medicines **Section 6.6.1.1**

**B.** Anti-infective Medicines -Medicines used in the management of HIV -Medicines for treating

**Opportunistic Infections in People living with HIV Section 6.7.5.1**

**\*\*Ciprofloxacin formulations are also listed in -**

**A. Section 6.2.2.3 - Anti-infective Medicines- Antibacterials - Other Antibacterials**

**B. Section 16.2 Ear, Nose and Throat Medicines**

**\*\*\*Povidone Iodine Also listed in Section 14.1.5 - Antiseptics and Disinfectants- Antiseptics**

**\*\*\*\*Prednisolone formulations are also listed in –**

**A. Section 3.7 - Antiallergics and Medicines used in Anaphylaxis**

**B. Section 7.2.4 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Hormones and anti-hormones used in cancer therapy**

**C. Section 18.1.5 - Hormones, other Endocrine Medicines and Contraceptives- Adrenal Hormones and synthetic substitutes**

**21.3- Local Anaesthetic**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
21.3.1	Proparacaine*	P,S,T	Drops 0.5 %

**21.4-Miotics and Antiglaucoma Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
21.4.1	Acetazolamide	P,S,T	Tablet 250 mg
21.4.2	Latanoprost	P,S,T	Drops 0.005 %
21.4.3	Pilocarpine	P,S,T	Drops 2 % Drops 4 %
21.4.4	Timolol	P,S,T	Drops 0.25 % Drops 0.5 %

**21.5-Mydriatics**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
21.5.1	Atropine**	P,S,T	Drops 1% Ointment 1%

**\*Proparacaine formulations are also listed in listed in Section 12.1.2 -**

**Diagnostic agents- Ophthalmic Medicines**

**\*\*Atropine formulations are also listed in –**

**A. Section 1.3.1 - Medicines used in Anaesthesia -Preoperative medication and sedation forshort term procedures**

**B. Section 4.2.1 - Antidotes and Other substances used in Management ofpoisoning/Envenomation - specific**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
--	----------	---------------------	--------------------------------

21.5.2	Homatropine	P,S,T	Drops 2%
21.5.3	Phenylephrine	P,S,T	Drops 5 % Drops 10 %
21.5.4	Tropicamide*	P,S,T	Drops 1 %

**21.6-Miscellaneous**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
21.6.1	Carboxymethylcellulose	P,S,T	Drops 0.5% Drops 1%
21.6.2	Hydroxypropyl methylcellulose	T	Injection 2%

**Section 22****Oxytocics and Antioxytocics****22.1 - Oxytocics and Abortifacient**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
22.1.1	Dinoprostone	S,T	Tablet 0.5 mg Gel 0.5 mg
22.1.2	Methylergometrine	P,S,T	Tablet 0.125 mg Injection 0.2 mg/mL

\*Tropicamide formulations are also listed in **Section 12.1.3 - Diagnostic agents - Ophthalmic Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
22.1.3	Mifepristone	P,S,T	Tablet 200 mg
22.1.4	Misoprostol	P,S,T	Tablet 100 mcg Tablet 200 mcg
22.1.5	Oxytocin	P,S,T	Injection 5 IU/mL Injection 10 IU/mL

**22.2 - Medicines used in Preterm Labour**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
22.2.1	Betamethasone	P,S,T	Injection 4 mg/mL

22.2.2	Nifedipine	S,T	Tablet 10 mg
<b>Section 23</b>			
<b>Medicines used in treatment of Psychiatric Disorders</b>			
<b>23.1 - Medicines used in Psychotic Disorders</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
23.1.1	Clozapine	T	Tablet 25 mg Tablet 50 mg Tablet 100 mg
23.1.2	Fluphenazine	P,S,T	Injection 25 mg/mL
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
23.1.3	Haloperidol*	S,T	Tablet 2 mg Tablet 5 mg Tablet 10 mg Tablet 20 mg Oral liquid 2 mg/5 mL Injection 5 mg/mL
23.1.4	Risperidone	P,S,T	Tablet 1 mg Tablet 2 mg Tablet 4 mg Oral liquid 1 mg/mL Injection (Long acting) 25 mg Injection (Long acting) 37.5 mg
<b>23.2 - Medicines used in Mood Disorders</b>			
<b>23.2.1 - Medicines used in Depressive Disorders</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
23.2.1.1	Amitriptyline**	P,S,T	Tablet 10 mg Tablet 25 mg Tablet 50 mg Tablet 75 mg
<p><i>*Haloperidol formulations are also listed in <b>Section 7.4.7 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative care- Medicines used in Palliative Care</b></i></p> <p><i>**Amitriptyline formulations are also listed in -</i></p> <p><b>A. Section 5.2.5 - Medicines used in Neurological Disorders - Anti-migraine medicines- For prophylaxis</b></p> <p><b>B. Section 7.4.2 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative care- Medicines used in Palliative Care</b></p>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
23.2.1.2	Escitalopram	P,S,T	Tablet 5 mg Tablet 10 mg Tablet 20 mg
			Capsule 10 mg

23.2.1.3	Fluoxetine*	P,S,T	Capsule 20 mg Capsule 40 mg Capsule 60 mg
----------	-------------	-------	---

**23.2.2 - Medicines used in Bipolar Disorders**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
23.2.2.1	Lithium	S,T	Tablet 300 mg
23.2.2.2	Sodium valproate**	P,S,T	Tablet 200 mg Tablet 300 mg Tablet 500 mg Modified Release – Tablet 300 mg Tablet 500 mg
23.2.2.3	Carbamazepine***	P,S,T	Tablet 100 mg Tablet 200 mg Tablet 400 mg Modified Release – Tablet 200 mg Tablet 400 mg Oral liquid 100 mg/5 mL (p)

\*Fluoxetine formulations are also listed in -

**A. Section 7.4.6 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative care- Medicines used in Palliative Care**

**B. Section 7.4.6 - Medicines used in treatment of psychiatric Disorders - Medicines used in obsessive compulsive disorders and panic attacks**

\*\* Sodium Valproate formulations are also listed in **Section 5.1.10 - Medicines used in Neurological Disorders -Anticonvulsants / antiepileptics**

\*\*\*Carbamazepine formulations are also listed in **Section 5.1.1 - Medicines used in Neurological Disorders- Anticonvulsants / antiepileptics**

**23.3 - Medicines used in Generalized Anxiety and Sleep Disorders**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
23.3.1	Clonazepam	P,S,T	Tablet 0.25 mg Tablet 0.5 mg Tablet 1 mg
23.3.2	Zolpidem	P,S,T	Tablet 5 mg Tablet 10 mg

**23.4 - Medicines used in Obsessive Compulsive Disorders and Panic attacks**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
--	----------	---------------------	--------------------------------

23.4.1	Clomipramine	P,S,T	Capsule 10 mg Capsule 25 mg Capsule 75 mg
23.4.2	Fluoxetine*	S,T	Capsule 10 mg Capsule 20 mg Capsule 40 mg Capsule 60 mg

\*Fluoxetine formulations are also listed in –

**A. Section 7.4.6 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative care- Medicines used in Palliative Care**

**B. Section 23.2.1.3 Medicines used in treatment of Psychiatric Disorders - Medicines used in mood disorders - Medicines used in depressive disorders**

### 23.5 Medicines used in Disorders due to Psychoactive substance abuse

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
23.5.1	Buprenorphine	P,S,T	Tablet (Sub-lingual) 0.4 mg
23.5.2	Buprenorphine (A) + Naloxone (B) –	P,S,T	Tablet (Sub-lingual) 0.4 mg (A) + 0.1 mg (B) Tablet (Sub-lingual) 2 mg (A) + 0.5 mg (B)
23.5.3	Nicotine (for nicotine replacement therapy)	P,S,T	Oral Dosage forms 2 mg Oral Dosage forms 4 mg

### Section 24

#### Medicines acting on the Respiratory tract

#### 24.1 - Antiasthmatic Medicines

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
24.1.1	Budesonide*	P,S,T	Inhalation (MDI/DPI) 100mcg/dose Inhalation (MDI/DPI) 200mcg/dose Respirator solution for use in nebulizer 0.5 mg/mL Respirator solution for use in nebulizer 1 mg/mL

\*Budesonide formulations are also listed in **Section 16.1 - Ear, Nose and Throat Medicines**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
24.1.2			Inhalation (MDI/DPI) 100 mcg(A) + 6 mcg (B) Inhalation (MDI/DPI) 200 mcg(A)

	Budesonide (A) + Formoterol (B)	P,S,T	+ 6 mcg (B) Inhalation (MDI/DPI) 400 mcg(A) + 6 mcg (B)
24.1.3	Hydrocortisone*	P,S,T	Powder for Injection 100 mg Powder for Injection 200 mg
24.1.4	Ipratropium	P,S,T	Inhalation (MDI/DPI) 20mcg/dose Respirator solution for use in nebulizer 250 mcg/mL
24.1.5	Montelukast	S,T	Tablet 4 mg Tablet 5 mg (including chewable tablets) Tablet 10 mg
24.1.6	Salbutamol	P,S,T	Tablet 2 mg Tablet 4 mg Oral liquid 2 mg/5 mL Inhalation (MDI/DPI*) 100mcg/dose Respirator Solution (Solution for Nebulizer 5 mg/mL)

\*Hydrocortisone formulations are also listed in -

**A. Section 3.5 - Antiallergics and Medicines used in Anaphylaxis**

**B. Section 18.1.3 - Hormones, other Endocrine Medicines and Contraceptives-Adrenal hormones and synthetic substitutes**

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
24.1.7	Tiotropium	P,S,T	Inhalation (MDI) 9 mcg/dose Inhalation (DPI) 18 mcg/dose

MDI- Metered Dose Inhaler

DPI- Dry Powder Inhaler

### Section 25

#### Solutions correcting Water, Electrolyte disturbances and Acid-base disturbances

	Medicine	Level of Healthcare	Dosage form(s) and strength(s)
25.1.1	Glucose*	P,S,T	Injection 5 % Injection 10 % Injection 25 % Injection 50 %
25.1.2	Glucose(A) + Sodium chloride (B)	P,S,T	Injection 5% (A) + 0.9 % (B)
25.1.3	Oral rehydrationsalts**	P,S,T	As licensed
25.1.4	Potassium chloride	P,S,T	Oral liquid 500 mg/5 mL

		S,T	Injection 150 mg/mL
*Glucose formulations are also listed in <b>Section 18.4.2.1 - Hormones, other Endocrine Medicines and Contraceptives - Medicines used in diabetes mellitus - Medicines used to treat hypoglycemia</b>			
**Oral rehydration salts are also listed in <b>Section 17.6.1 - Gastrointestinal Medicines - Medicines used in diarrhea</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
25.1.5	Ringer lactate	P,S,T	Injection (as per IP)
25.1.6	Sodium bicarbonate	P,S,T	Injection (as per IP)
25.1.7	Sodium chloride	P,S,T	Injection 0.9%
		S,T	Injection 3%
<b>25.2-Miscellaneous</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
25.2.1	Water for Injection	P,S,T	Injection
<b>Section 26</b>			
<b>Vitamins and Minerals</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
26.1	Ascorbic acid(Vitamin C)	P,S,T	Tablet 100 mg Tablet 500 mg
26.2	Calcium carbonate	P,S,T	Tablet 625 mg (equivalent to elemental calcium 250 mg) Tablet 1250 mg (equivalent to elemental calcium 500 mg)
26.3	Calcium gluconate*	P,S,T	Injection 100 mg/mL
26.4	Cholecalciferol	P,S,T	Solid oral dosage form 1000 IU Solid oral dosage form 60000 IU Oral liquid 400 IU/mL
*Calcium Gluconate formulations are also listed in <b>Section 4.2.2 - Antidotes and Other substances used in poisoning/Envenomation -Specific</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
26.5	Pyridoxine	P,S,T	Tablet 10 mg Tablet 50 mg Tablet 100 mg
26.6	Riboflavin	P,S,T	Tablet 10 mg
26.7	Thiamine	P,S,T	Tablet 100 mg Injection 100 mg/mL
			Capsule/Tablet 50000 IU (including Chewable Tablet) Oral liquid 100000 IU/mL Injection 50000



26.8	Vitamin A	P,S,T	IU/mL
<b>Section 27</b>			
<b>Medicines for COVID-19 management</b>			
27.1	Dexamethasone*	P,S,T	Tablet 0.5 mg Tablet 2 mg Tablet 4 mg Oral liquid 0.5 mg/5 mL (p) Injection 4 mg/mL
27.2	Enoxaparin**	S,T	Injection 40 mg/ 0.4 mL Injection 60 mg/ 0.6 mL
*Dexamethasone is also listed in -			
A. <b>Section 3.4 - Antiallergics and Medicines used in Anaphylaxis</b>			
B. <b>Section 7.4.3 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative care- Medicines used in Palliative Care</b>			
C. <b>Section 18.1.1 - Hormones, other Endocrine Medicines and Contraceptives - Adrenal hormones and synthetic substitutes</b>			
**Enoxaparin is also listed in -			
A. <b>Section 8.2.1 - Medicines affecting Blood - Medicines affecting coagulation</b>			
B. <b>Section 10.5.4 - Cardiovascular medicines - Antiplatelet and Antithrombotic Medicines</b>			
	<b>Medicine</b>	<b>Level of Healthcare</b>	<b>Dosage form(s) and strength(s)</b>
27.3	Methylprednisolone*	S,T	Injection 40 mg/mL
27.4	Paracetamol**	P,S,T	Tablet 500 mg Tablet 650 mg Oral liquid 120 mg/5 mL (p) Oral Liquid 125 mg/5 mL (p) Oral Liquid 250 mg/5 mL (p)
27.5	Oxygen***	P,S,T	As licensed for medical purpose
*Methylprednisolone is also listed in <b>Section 18.1.4 - Hormones, other Endocrine medicines and Contraceptives- Adrenal Hormones and synthetic substitutes</b>			
**Paracetamol is also listed in			
A. <b>Section 2.1.5 - Analgesics, antipyretics, non-steroidal anti-inflammatory medicines, medicines used to treat Gout and disease Modifying agents used in Rheumatoid Disorders-Non-opioid analgesics, antipyretics and nonsteroidal anti-inflammatory medicines</b>			
B. <b>Section 5.2.3 - Medicines used in Neurological Disorders-Antimigraine medicines</b>			
*** Oxygen is also listed in Medicines used in <b>Section 1.1.5 - Anaesthesia- General Anaesthetics and Oxygen</b>			

<b>Section 28</b>	
<b>Coronary Stents</b>	
28.1	Bare Metal Stents (BMS)
28.2	Drug Eluting Stents (DES) which include metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable stents
<b>Section 29</b>	
<b>Medicines for animal use</b>	
29.1	Foot and Mouth Disease (Trivalent) Oil adjuvant vaccine
29.2	Brucella Abortus (S19 strain) Vaccine, Live Freeze Dried

All modified release formulations of same strength such as sustained release, controlled release, extended release, prolonged release etc. are included.

#### **Explanation.**

1. Any dosage form of a medicine other than that included in this schedule, but in same strength and route of administration, which does not demonstrate significant difference in terms of pharmacokinetics/ pharmacodynamics/ efficacy / safety over the dosage form mentioned in the list, should be considered as included. To elaborate, if tablet is included, other oral solid dosage form such as capsule is considered as included. However, such different dosage forms should be considered differently for purposes of procurement policy, pricing etc. This principle also applies to all other dosage forms e.g. oral liquid dosage forms, injectables, topical dosage forms etc.
2. In general, medicines have been mentioned in this schedule M in terms of their active moieties, without mentioning the salts. In case, a medicine is available in more than one salt without any significant difference in potency / pharmacokinetics / pharmacodynamics / efficacy-safety profile aspects, it indicates that these salts are therapeutically similar. Therefore, all salts of such medicines with specified dosage form and strength are considered included in this schedule. In case, where the different salts of a medicine have significant difference in potency / pharmacokinetics / pharmacodynamics / efficacy-safety profile, the medicine has been mentioned in this schedule with respect to its specific salt.
3. Different isomers of a molecule may differ with respect to potency / pharmacodynamics / safety-efficacy profile. Such different isomers have been considered as separate entities. Therefore, inclusion of one isomer of a molecule in this schedule does not imply inclusion of all other isomers of a molecule.
4. Prodrugs / analogues / derivatives of one active moiety are available as different medicines. They may differ with respect to potency / pharmacokinetics / pharmacodynamics / safety-efficacy profile. Inclusion of one form of such medicines in the schedule will not imply inclusion of other forms.
5. Vaccines, sera and immunoglobulins are complex biological products, which may be manufactured from various sources, by using different processes and technologies. In such cases, irrespective of variation in source, composition, or strengths, all the products of the same vaccine/ sera/ immunoglobulin, as approved by licensing authority are considered as included in this schedule.
6. Innovation in medicine must be encouraged. The formulations developed through incremental innovation or novel drug delivery systems like lipid/liposomal formulations etc. should be considered as included only if specified in the list against any medicine. Such different formulations should be considered differently for purposes such as procurement policy, pricing, etc.
7. For injectable preparations, the pack size (single and multi-dose packs) has not been mentioned. It is suggested that the single and multi-dose pack sizes be considered as separate entities for purposes such as procurement/pricing etc.”.

[F. No. 31026/47/2022-Pricing]

AWADHESH KUMAR CHOUDHARY, Sr. Economic Advisor

**Note :** The principal order was published in the Gazette of India, Extraordinary, Part II, section 3, sub-section (ii), *vide* number S.O. 1221 (E), dated the 15<sup>th</sup> May, 2013 and was subsequently amended *vide* notifications numbers: -

- (i) S.O. 686(E), dated the 9<sup>th</sup> March, 2015;
- (ii) S.O. 1233(E), dated the 8<sup>th</sup> May, 2015;
- (iii) S.O. 701(E), dated the 10<sup>th</sup> March, 2016;
- (iv) S.O. 1192(E), dated the 22<sup>nd</sup> March, 2016;
- (v) S.O. 4100(E), dated the 21<sup>st</sup> December, 2016;
- (vi) S.O. 39(E), dated the 3<sup>rd</sup> January, 2019;
- (vii) S.O. 508(E), dated the 1<sup>st</sup> February, 2021;
- (viii) S.O. 2899(E), dated the 20<sup>th</sup> July, 2021; and
- (ix) S.O. 3249(E), dated the 12<sup>th</sup> August, 2021.